

# Godrej Consumer

|                  |   |
|------------------|---|
| Estimate changes | ↔ |
| TP change        | ↓ |
| Rating change    | ↔ |

|                       |            |
|-----------------------|------------|
| Bloomberg             | GCPL IN    |
| Equity Shares (m)     | 1023       |
| M.Cap.(INRb)/(USD\$)  | 856.6 / 9  |
| 52-Week Range (INR)   | 1275 / 810 |
| 1, 6, 12 Rel. Per (%) | -3/-18/-12 |
| 12M Avg Val (INR M)   | 1635       |

## Financials & Valuations (INR b)

| Y/E March       | 2027E | 2028E | 2029E |
|-----------------|-------|-------|-------|
| Sales           | 181.4 | 201.0 | 221.4 |
| Sales Gr. (%)   | 19.5  | 10.8  | 10.2  |
| EBITDA          | 35.6  | 40.5  | 45.4  |
| EBITDA mrg. (%) | 19.7  | 20.1  | 20.5  |
| Adj. PAT        | 23.4  | 28.0  | 32.1  |
| Adj. EPS (INR)  | 22.9  | 27.4  | 31.4  |
| EPS Gr. (%)     | 15.4  | 19.7  | 14.6  |
| BV/Sh.(INR)     | 124.6 | 128.0 | 133.4 |

## Ratios

|            |      |      |      |
|------------|------|------|------|
| RoE (%)    | 18.4 | 21.7 | 24.0 |
| RoCE (%)   | 15.6 | 18.9 | 21.5 |
| Payout (%) | 96.1 | 87.6 | 82.8 |

## Valuations

|                |      |      |      |
|----------------|------|------|------|
| P/E (x)        | 36.4 | 30.4 | 26.5 |
| P/BV (x)       | 6.7  | 6.5  | 6.3  |
| EV/EBITDA (x)  | 24.4 | 21.4 | 18.9 |
| Div. Yield (%) | 2.6  | 2.9  | 3.1  |

## Shareholding Pattern (%)

| As On    | Sep-26 | Jun-26 | Sep-25 |
|----------|--------|--------|--------|
| Promoter | 53.1   | 53.1   | 53.1   |
| DII      | 20.7   | 19.6   | 13.6   |
| FII      | 11.0   | 12.3   | 18.2   |
| Others   | 15.2   | 15.0   | 15.1   |

FII includes depository receipts

**CMP: INR837**

**TP: INR1,050 (+25%)**

**Buy**

## Strong revenue momentum; RM inflation remains a drag

- GCPL's consolidated revenue grew 19% YoY to INR44.1b (in line) in 2QFY27, with volume growth at 8%, driven by broad-based momentum across regions. Consol. EBITDA grew 12% YoY to INR8.2b (in line), as elevated input-cost inflation led to a 300bp contraction in gross margin, limiting earnings conversion. India EBITDA grew 8% YoY, while international profitability remained strong, led by 43% EBITDA growth in GAUM and 12% growth in Indonesia.
- India revenue grew 13% YoY to INR26.3b (in line), with underlying volume growth of 7%, despite an estimated ~150bp impact from trade inventory correction. Home Care led with 19% value growth, while Personal Care grew 8%, aided by a favorable base. In Personal Care, price hikes and grammage cuts weighed on soaps, alongside inventory correction in larger packs.
- International revenue registered robust 34% growth. Indonesia delivered 20% sales growth and 8% UVG, supported by El Niño-led tailwinds for household insecticides and traction from the Stella LV relaunch. While weather provided a near-term boost, management expects healthy underlying growth to sustain going forward. GAUM continued to outperform, with revenue growing 40% YoY (23% CC) and UVG of 16%.
- High-single-digit input-cost inflation across India and Indonesia is expected to intensify mildly in 3QFY27. Management is prioritizing EBITDA growth over margin protection through calibrated pricing and cost savings. Further price increases are planned in soaps and liquid detergents, where margins remain below normative levels.
- Near-term margin pressure is likely to persist amid elevated commodity inflation. However, calibrated pricing and cost-saving initiatives should support absolute EBITDA growth. We expect international growth momentum to sustain, with Indonesia's macros and weather-led tailwinds and capacity expansion in GAUM remaining key monitorables. GCPL maintained its FY27 guidance of high-single-digit standalone UVG and double-digit consolidated revenue and EBITDA growth. **We maintain BUY rating with a TP of INR1,050, based on 35x Sep'28E EPS.**

## In-line performance, navigating inflationary pressure

- **Healthy India growth despite inventory correction:** Standalone net sales (including OOI) grew 13% YoY to INR26.3b (est. INR26.1b), with UVG of 7% despite an estimated ~150bp impact from trade inventory correction. Home Care delivered 19% value growth, led by air fresheners and home care liquids, while Personal Care grew 8%, aided by a favorable base. Gross margin contracted 470bp YoY to 46.1%, reflecting elevated input costs, while GP grew 2% YoY. EBITDA margin declined 90bp YoY to 21.2% (est. 21.6%), partly supported by lower ad spends. EBITDA grew 8% YoY to INR5.6b (est. INR5.7b).

**Naveen Trivedi – Research Analyst** (Naveen.Trivedi@MotilalOswal.com)

**Research Analyst: Amey Tiwari** (Amey.Tiwari@MotilalOswal.com) | **Tanu Jindal** (Tanu.Jindal@MotilalOswal.com)

**Investors are advised to refer through important disclosures made at the last page of the Research Report.**

Motilal Oswal research is available on [www.motilaloswal.com/Institutional-Equities](http://www.motilaloswal.com/Institutional-Equities), Bloomberg, Thomson Reuters, Factset and S&P Capital.

- **International growth remains broad-based:** Indonesia delivered 20% sales growth with 8% UVG, supported by broad-based category momentum and El Niño-led tailwinds for household insecticides. The Stella LV relaunch and newer formats continue to support growth, although the weather-led benefit is expected to moderate in 2HFY27. GAUM reported 40% revenue growth in INR terms (23% in CC) and 16% UVG, with strength across categories and geographies. EBITDA grew 43% YoY, reflecting operating leverage, while capacity constraints in some businesses remain a near-term growth bottleneck, with expansions expected over the next two months.
- **Input-cost inflation weighs on margins:** Consolidated net sales grew 19% YoY to INR44.1b (est. INR44.3b), with volume growth of 8%. Gross margin contracted 300bp YoY to 47.6% (est. 47.2%) amid high-single-digit input-cost inflation across India and Indonesia. EBITDA margin declined 120bp YoY to 18.6% (est. 18.7%), while EBITDA grew 12% YoY to INR8.2b (est. INR8.3b). Higher interest costs and lower other income limited PBT growth to 8% YoY at INR7.0b (est. INR7.3b), while APAT grew 10% YoY to INR5.3b (est. INR5.5b).
- Management maintained FY27 guidance of high-single-digit standalone UVG and double-digit **consolidated** revenue and EBITDA growth, prioritizing absolute profit growth over margin protection through calibrated pricing and cost-saving initiatives.

#### Highlights from the management commentary

- Inflation across crude-linked derivatives, palm oil and other commodities was among the highest in years, with a high single-digit impact on India and Indonesia.
- Commodity inflation is likely to be mildly higher in 3Q vs. 2Q.
- Soaps and liquid detergents margins remain below normative levels, so more calibrated price increases are planned in these two categories.
- Soaps saw trade inventory correction, concentrated in larger SKUs, alongside a price-volume recalibration as rounds of industry price hikes play out.
- Godrej Fab maintained double-digit growth, with detergent volumes unaffected by inflation as the category benefits from formalization and a shift from powders to liquids.

#### Valuation and view

- We maintain our EPS estimates for FY27-FY29E.
- Management focuses on delivering high-single-digit UVG in India and double-digit consolidated revenue and EBITDA growth in FY27. GAUM continues to deliver strong growth and profitability, while Indonesia's momentum remains healthy. Elevated commodity inflation is likely to keep near-term margins under pressure. However, calibrated pricing and cost-saving initiatives should support absolute EBITDA growth, with margin recovery hinging on pricing realization and input-cost trends.
- The company is expanding its TAM by foraying into new, faster-growing categories, such as men's face wash, stain removers and toilet cleaners, and continues to strengthen its core portfolio. Besides, the company has made consistent efforts to address gaps in profitability and growth across its international business. The company has guided for double-digit consolidated revenue and EBITDA growth in FY27. We model a 14%/13% revenue/EBITDA CAGR over FY26-29E. **We maintain BUY rating with a TP of INR1,050, based on 35x Sep'28E EPS.**

## Quarterly Performance (Consolidated)

(INR m)

| Y/E March                  | FY26   |        |        |        | FY27E  |        |        |        | FY26     | FY27E    | FY27E  | Var.  |
|----------------------------|--------|--------|--------|--------|--------|--------|--------|--------|----------|----------|--------|-------|
|                            | 1Q     | 2Q     | 3Q     | 4Q     | 1Q     | 2Q     | 3QE    | 4QE    |          |          | 2QE    | (%)   |
| Domestic volume Growth (%) | 5      | 3      | 9      | 8      | 7      | 7      | 9      | 10     | 6        | 8        | 8      |       |
| Net Sales (including OOI)  | 35,713 | 37,082 | 39,980 | 39,004 | 42,255 | 44,131 | 48,344 | 46,655 | 1,51,779 | 1,81,385 | 44,278 | -0.3  |
| YoY change (%)             | 9.7    | 3.9    | 9.3    | 11.0   | 18.3   | 19.0   | 20.9   | 19.6   | 8.4      | 19.5     | 19.4   |       |
| Gross Profit               | 18,100 | 18,762 | 20,661 | 20,312 | 20,313 | 21,025 | 22,847 | 22,517 | 77,835   | 86,702   | 20,883 | 0.7   |
| Margin (%)                 | 50.7   | 50.6   | 51.7   | 52.1   | 48.1   | 47.6   | 47.3   | 48.3   | 51.3     | 47.8     | 47.2   |       |
| Other Operating Exp.       | 11,154 | 11,429 | 11,857 | 11,898 | 12,299 | 12,825 | 12,963 | 12,965 | 46,337   | 51,053   | 12,588 | 1.9   |
| EBITDA                     | 6,946  | 7,333  | 8,804  | 8,414  | 8,013  | 8,200  | 9,884  | 9,553  | 31,497   | 35,650   | 8,296  | -1.2  |
| Margins (%)                | 19.4   | 19.8   | 22.0   | 21.6   | 19.0   | 18.6   | 20.4   | 20.5   | 20.8     | 19.7     | 18.7   |       |
| YoY growth (%)             | -4.4   | -3.7   | 16.5   | 10.8   | 15.4   | 11.8   | 12.3   | 13.5   | 4.9      | 13.2     | 13.1   |       |
| Depreciation               | 594    | 656    | 664    | 761    | 752    | 778    | 775    | 785    | 2,675    | 3,089    | 750    | 3.8   |
| Interest                   | 865    | 759    | 789    | 903    | 860    | 873    | 825    | 804    | 3,316    | 3,361    | 850    | 2.7   |
| Other Income               | 845    | 629    | 559    | 694    | 519    | 505    | 550    | 668    | 2,662    | 2,242    | 575    | -12.1 |
| PBT                        | 6,332  | 6,547  | 7,910  | 7,444  | 6,921  | 7,054  | 8,834  | 8,633  | 28,168   | 31,441   | 7,271  | -3.0  |
| Tax                        | 1,613  | 1,657  | 2,021  | 1,997  | 1,720  | 1,736  | 2,253  | 2,247  | 7,287    | 7,955    | 1,818  |       |
| Rate (%)                   | 25.5   | 25.3   | 25.5   | 26.8   | 24.9   | 24.6   | 25.5   | 26.0   | 25.9     | 25.3     | 25.0   |       |
| Adj PAT                    | 4,669  | 4,811  | 5,662  | 5,162  | 5,161  | 5,296  | 6,581  | 6,386  | 20,304   | 23,424   | 5,453  | -2.9  |
| YoY change (%)             | 0.4    | -2.9   | 12.7   | 19.5   | 10.6   | 10.1   | 16.2   | 23.7   | 7.2      | 15.4     | 13.3   |       |
| Extraordinaries            | -144   | -218   | -683   | -645   | -116   | -67    | 0      | 0      | -1,689   | -183     | 0      |       |
| Reported PAT               | 4,525  | 4,593  | 4,979  | 4,518  | 5,045  | 5,229  | 6,581  | 6,386  | 18,615   | 23,242   | 5,453  | -4.1  |

E: MOFSL Estimate

## Indian business segment highlights

- **The home care business registered 19% revenue growth.**
  - **Household Insecticides:** The electrics portfolio delivered sequentially improving performance, supported by the new “6-minute” campaign, while incense sticks continued to scale strongly. Non-mosquito continues to witness momentum.
  - **Air Fresheners** sustained strong double-digit growth and category leadership. Aer Spray 99 continues to reset the category landscape and grow significantly ahead of peers and gain share. Aer O continues to scale and strengthen its presence in the category with strong growth momentum
  - **Fabric Care:** Godrej Fab maintained its strong double-digit growth trajectory and continued to strengthen its market position.
  - **Godrej Spic** was scaled nationally during 1Q, continues to witness healthy consumer repeats and sequential growth, with significant distribution headroom still available.
  - Godrej Rizz (Liquid Dishwash) was expended in select markets across West and South India.
  - It launched Godrej Zap, entering into stain removers.
- **The personal care recorded a revenue growth of 8%.**
  - **Personal Wash:** Soaps remained stable despite significant price increases and grammage reductions, although with a favorable comparator. The premium liquid formats continue to do well. Cinthol Bodywash continues to scale sequentially, while Muuchstac face wash progressing in line with GCPL expectations. Magic Handwash continues to scale and enjoy market leadership in the handwash segment.
  - **Hair Color** maintained its growth momentum and continued to gain market share. GCPL launched Hair Lab, marking its entry into the premium hair color segment.
  - **Perfumes & Deodorants** delivered double-digit growth, supported by healthy UVG in deodorants and continued momentum in perfumes and EDPs.

**Exhibit 1: Snapshot of 2QFY27 performance as reported by the company**

| Growth (%)                    | Consolidated | Standalone |
|-------------------------------|--------------|------------|
|                               | Reported     | Reported   |
| <b>UVG</b>                    | <b>8</b>     | <b>7</b>   |
| Net sales                     | 19           | 13         |
| Net sales (constant currency) | 15           | -          |
| EBITDA                        | 12           | 8          |
| Net profit (reported)         | 14           | -5         |

Source: Company, MOFSL

**Exhibit 2: Snapshot of sales by geography**

| International business              | 2QFY27        |            |               |
|-------------------------------------|---------------|------------|---------------|
|                                     | Sales (INR m) | Growth (%) | CC growth (%) |
| India – Reported                    | 26,310        | 13         | -             |
| Indonesia                           | 5,380         | 20         | 20            |
| Africa, USA & Middle East (organic) | 10,690        | 40         | 23            |
| Latin America and SAARC             | 2,970         | 43         | 28            |
| <b>Total net sales (Reported)</b>   | <b>43,960</b> | <b>19</b>  | <b>15</b>     |

Source: Company, MOFSL



## Highlights from the conference call

### Business operations and environment

- Standalone sales grew 13% on 7% UVG despite a ~150bp hit from trade inventory correction, which mildly dented standalone EBITDA.
- Inventory is being brought down to system-defined levels so the sales team focuses purely on offtake, as part of an operational-excellence push.
- Subdued monsoon in India was offset by El Niño tailwinds in Indonesia, though El Niño's impact was weighted to 1H, and HI looks fine for 2H.
- Digital advertising capability is being rebuilt, with GCPL targeting top-percentile capability in each category over the next few quarters, driven by influencers and digital rather than spend share.
- India CEO hire is under way, with the focus on getting the right person (Godrej values, entrepreneurial mindset) over a quick appointment.
- Godrej Spic (toilet cleaner) has gone national after meeting its repeat milestones in Tamil Nadu, with pet care still at a learning stage.
- **FY27 guidance is maintained at high single-digit standalone UVG and double-digit consolidated revenue and EBITDA growth.**

### Costs and Margins

- Inflation across crude-linked derivatives, palm oil and other commodities was among the highest in years, with a high single-digit impact on India and Indonesia.
- Commodity inflation is likely to be mildly higher in 3Q vs. 2Q.
- Pricing is set for profit growth rather than margin, with focus on EBITDA growth over EBITDA percentage.
- Soaps and liquid detergents margins remain below normative levels, so more calibrated price increases are planned in these two categories.
- Large cost-saving programs, trade-level optimization and higher-ROI digital investments are being used to keep share of voice range-bound.

### Home care

- Home Care grew 19% in value, led by air fresheners and home care liquids, and HI gained market share, which management reads as early proof that actions across brands are working.
- HI's electrics portfolio improved sequentially on the new campaign, while incense sticks continued to scale strongly.
- Godrej Fab kept up double-digit growth, with detergent volumes holding despite inflation, aided by industry formalization and a shift from powders to liquids. Ezee is also seeing good early traction as the season begins.
- New launches are widening the portfolio: Godrej Rizz (liquid dishwasher) in select West and South markets and Godrej Zap (stain removers) were both received well.
- Spic has gone national on healthy consumer repeats, with significant distribution headroom left.

### **Personal care**

- Personal Care grew 8% in value, aided by a favorable base, despite soaps seeing significant price increases and grammage cuts.
- Soaps saw trade inventory correction, concentrated in larger SKUs, alongside a price-volume recalibration as rounds of industry price hikes play out.
- Premium liquids continued to do well, with Cinthol Bodywash scaling sequentially.
- Muuchstac face wash is progressing ahead of its business plan.
- Hair colors kept up growth momentum and gained market share across key bets.
- Perfumes and deodorants grew strong double digits on healthy deo volumes and momentum in perfumes and EDPs.

### **International business**

- Indonesia sales grew 20% with 8% UVG, and EBITDA rose 12% even as LPG prices doubled.
- Part of Indonesia's growth is weather-led (El-Nino), but double-digit UVG is seen as sustainable on new formats (LV, Pocket) and multiple growth levers.
- GAUM sales grew 40% in INR terms (23% in cc) on 16% UVG, with EBITDA up 43%.
- GAUM growth is broad-based across categories, with new hair products and hair color growing double-digit volumes for last 7-8 quarters.
- GAUM capacity utilization is constraining growth in some existing businesses, with expansions due in the next two months.
- Aer incense sticks launched in Africa with good early traction.

## Key exhibits

| Segment revenue (INR m)                | 2QFY25        | 3QFY25        | 4QFY25        | 1QFY26        | 2QFY26        | 3QFY26        | 4QFY26        | 1QFY27        | 2QFY27        |
|----------------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| India                                  | 23,007        | 22,617        | 21,608        | 23,300        | 23,526        | 24,658        | 23,608        | 25,574        | 26,541        |
| Indonesia                              | 5,138         | 5,079         | 5,043         | 4,223         | 4,482         | 4,600         | 4,922         | 4,869         | 5,383         |
| Africa (including SON)                 | 6,446         | 7,724         | 6,903         | 6,840         | 7,631         | 9,070         | 8,004         | 10,061        | 10,705        |
| Others                                 | 2,476         | 2,636         | 2,572         | 2,201         | 2,024         | 2,390         | 3,151         | 2,583         | 2,841         |
| Less: Inter-segment eliminations       | -403          | -371          | -388.3        | -500.3        | -580          | -739          | -680          | -833          | -1339         |
| <b>Net Sales from operations</b>       | <b>36,663</b> | <b>37,684</b> | <b>35,739</b> | <b>36,064</b> | <b>37,082</b> | <b>39,980</b> | <b>39,004</b> | <b>42,255</b> | <b>44,131</b> |
| Segment revenue growth (%)             |               |               |               |               |               |               |               |               |               |
| India                                  | 6.1           | 2.6           | 6.3           | 7.7           | 2.3           | 9.0           | 9.3           | 9.8           | 12.8          |
| Indonesia                              | 8.6           | 8.9           | 1.2           | -9.2          | -12.8         | -9.4          | -2.4          | 15.3          | 20.1          |
| Africa (including SON)                 | -21.0         | -16.3         | 16.3          | 25.6          | 18.4          | 17.4          | 15.9          | 47.1          | 40.3          |
| Others                                 | 35.6          | 165.4         | -11.3         | 12.7          | -18.2         | -9.3          | 22.5          | 17.4          | 40.4          |
| Less: Inter-segment eliminations       | 7.0           | 10.5          | 29.3          | 37.5          | 44.1          | 99.2          | 75.0          | 66.5          | 130.7         |
| <b>Net Sales from operations</b>       | <b>1.8</b>    | <b>3.0</b>    | <b>5.6</b>    | <b>8.2</b>    | <b>1.1</b>    | <b>6.1</b>    | <b>9.1</b>    | <b>17.2</b>   | <b>19.0</b>   |
| Segment EBIT (INR m)                   |               |               |               |               |               |               |               |               |               |
| India                                  | 6,068         | 5,382         | 5,040         | 5,321         | 5,104         | 6,063         | 5,777         | 5,282         | 5,217         |
| Indonesia                              | 1,092         | 1,187         | 1,472         | 1,063         | 1,047         | 1,211         | 1,484         | 1,176         | 1,175         |
| Africa (including SON)                 | 769           | 1014          | 999           | 733           | 926           | 1141          | 967           | 1027          | 1349          |
| Others                                 | 146           | 300           | 210           | 202           | 345           | 312           | 295           | 336           | 214           |
| Less: Inter-segment eliminations       | -120          | -112          | -117          | -122          | -118          | -3            | -176          | -40           | -29           |
| <b>Net EBIT from operations</b>        | <b>7,955</b>  | <b>7,772</b>  | <b>7,603</b>  | <b>7,197</b>  | <b>7,305</b>  | <b>8,725</b>  | <b>8,347</b>  | <b>7,781</b>  | <b>7,927</b>  |
| Segment EBIT growth (%)                |               |               |               |               |               |               |               |               |               |
| India                                  | -11.1         | -20.4         | -13.0         | -6.7          | -15.9         | 12.7          | 14.6          | -0.7          | 2.2           |
| Indonesia                              | 7.7           | 1.8           | 10.5          | -9.3          | -4.0          | 2.0           | 0.9           | 10.6          | 12.2          |
| Africa (including SON)                 | 54.1          | 23.0          | 50.1          | 17.2          | 20.4          | 12.5          | -3.2          | 40.1          | 45.6          |
| Others                                 | 319.2         | 1115.8        | 183.3         | 38.2          | 136.0         | 3.9           | 40.2          | 66.1          | -37.9         |
| <b>Net EBIT from operations</b>        | <b>12.2</b>   | <b>-9.3</b>   | <b>-1.2</b>   | <b>-4.3</b>   | <b>-8.2</b>   | <b>12.3</b>   | <b>9.8</b>    | <b>8.1</b>    | <b>8.5</b>    |
| Segment EBIT mix (%)                   |               |               |               |               |               |               |               |               |               |
| India                                  | 76            | 69            | 66            | 74            | 70            | 69            | 69            | 68            | 66            |
| Indonesia                              | 14            | 15            | 19            | 15            | 14            | 14            | 18            | 15            | 15            |
| Africa (including SON)                 | 10            | 13            | 13            | 10            | 13            | 13            | 12            | 13            | 17            |
| Others                                 | 2             | 4             | 3             | 3             | 5             | 4             | 4             | 4             | 3             |
| Less: Inter-segment eliminations       | -2            | -1            | -2            | -2            | -2            | 0             | -2            | -1            | 0             |
| <b>Net EBIT from operations</b>        | <b>100</b>    | <b>100</b>    | <b>100</b>    | <b>100</b>    | <b>100</b>    | <b>100</b>    | <b>100</b>    | <b>100</b>    | <b>100</b>    |
| Segment EBIT margin (%)                |               |               |               |               |               |               |               |               |               |
| India                                  | 26.4          | 23.8          | 23.3          | 22.8          | 21.7          | 24.6          | 24.5          | 20.7          | 19.7          |
| Indonesia                              | 21.2          | 23.4          | 29.2          | 25.2          | 23.4          | 26.3          | 30.2          | 24.1          | 21.8          |
| Africa (including SON)                 | 11.9          | 13.1          | 14.5          | 10.7          | 12.1          | 12.6          | 12.1          | 10.2          | 12.6          |
| Others                                 | 5.9           | 11.4          | 8.2           | 9.2           | 17.1          | 13.1          | 9.4           | 13.0          | 7.5           |
| <b>Net EBIT margin from operations</b> | <b>21.7</b>   | <b>20.6</b>   | <b>21.3</b>   | <b>20.0</b>   | <b>19.7</b>   | <b>21.8</b>   | <b>21.4</b>   | <b>18.4</b>   | <b>18.0</b>   |
| Segment EBIT margin change (%)         |               |               |               |               |               |               |               |               |               |
| India                                  | -5.1          | -6.9          | -5.2          | -3.5          | -4.7          | 0.8           | 1.1           | -2.2          | -2.0          |
| Indonesia                              | -0.2          | -1.6          | 2.5           | 0.0           | 2.1           | 3.0           | 1.0           | -1.0          | -1.5          |
| Africa (including SON)                 | 5.8           | 4.2           | 3.3           | -0.8          | 0.2           | -0.5          | -2.4          | -0.5          | 0.5           |
| Others                                 | 4.0           | 8.9           | 5.6           | 1.7           | 11.1          | 1.7           | 1.2           | 3.8           | -9.5          |
| <b>Overall EBIT change</b>             | <b>2.0</b>    | <b>-2.8</b>   | <b>-1.5</b>   | <b>-2.6</b>   | <b>-2.0</b>   | <b>1.2</b>    | <b>0.1</b>    | <b>-1.5</b>   | <b>-1.7</b>   |

## Valuation and view


- We maintain our EPS estimates for FY27-FY29E.
- Management remains focused on delivering high-single-digit UVG in India and double-digit consolidated revenue and EBITDA growth in FY27. GAUM continues to deliver strong growth and profitability, while Indonesia's momentum remains healthy. Elevated commodity inflation is likely to keep near-term margins under pressure. However, calibrated pricing and cost-saving initiatives should support absolute EBITDA growth, with margin recovery hinging on pricing realization and input-cost trends.
- The company is expanding its TAM by foraying into new, faster-growing categories, such as men's face wash, stain removers and toilet cleaners, and continues to strengthen its core portfolio. Besides, the company has made consistent efforts to address gaps in profitability and growth across its international business. The company has guided for double-digit consolidated revenue and EBITDA growth in FY27. We model a 14%/13% revenue/EBITDA CAGR over FY26-29E. **We maintain BUY rating with a TP of INR1,050, based on 35x Sep'28E EPS.**

**Exhibit 3: We maintain our EPS estimates for FY27-FY29E**

| INR bn | New   |       |       | Old   |       |       | Change |       |       |
|--------|-------|-------|-------|-------|-------|-------|--------|-------|-------|
|        | FY27E | FY28E | FY29E | FY27E | FY28E | FY29E | FY27E  | FY28E | FY29E |
| Sales  | 181.4 | 201.0 | 221.4 | 178.9 | 198.0 | 217.9 | 1.4    | 1.5   | 1.6   |
| EBITDA | 35.6  | 40.5  | 45.4  | 35.8  | 41.0  | 45.9  | -0.5   | -1.4  | -1.0  |
| PAT    | 23.4  | 28.0  | 32.1  | 23.7  | 28.6  | 32.6  | -1.2   | -2.0  | -1.5  |


Source: Company, MOFSL

**Exhibit 4: P/E ratio (x) for GCPL**



Source: Company, MOFSL

**Exhibit 5: P/E ratio (x) for the Consumer sector**



Source: Company, MOFSL

## Financials and valuations

| Income Statement          |              |              |              |              |              |              | (INR b)      |              |              |
|---------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| Y/E March                 | 2021         | 2022         | 2023         | 2024         | 2025         | 2026         | 2027E        | 2028E        | 2029E        |
| <b>Net Sales</b>          | <b>110.3</b> | <b>122.8</b> | <b>133.2</b> | <b>141.0</b> | <b>140.0</b> | <b>151.8</b> | <b>181.4</b> | <b>201.0</b> | <b>221.4</b> |
| Change (%)                | 11.3         | 11.3         | 8.5          | 5.9          | -0.7         | 8.4          | 19.5         | 10.8         | 10.2         |
| <b>Gross Profit</b>       | <b>61.0</b>  | <b>62.0</b>  | <b>66.1</b>  | <b>77.8</b>  | <b>74.6</b>  | <b>77.8</b>  | <b>86.7</b>  | <b>100.0</b> | <b>112.0</b> |
| Margin (%)                | 55.3         | 50.5         | 49.7         | 55.2         | 53.3         | 51.3         | 47.8         | 49.7         | 50.6         |
| Total Expenditure         | 87.0         | 97.8         | 107.8        | 110.3        | 109.9        | 120.3        | 145.7        | 160.5        | 176.0        |
| <b>EBITDA</b>             | <b>23.3</b>  | <b>24.9</b>  | <b>25.4</b>  | <b>30.7</b>  | <b>30.0</b>  | <b>31.5</b>  | <b>35.6</b>  | <b>40.5</b>  | <b>45.4</b>  |
| Change (%)                | 9.3          | 6.8          | 1.9          | 20.9         | -2.2         | 4.9          | 13.2         | 13.6         | 12.2         |
| Margin (%)                | 21.2         | 20.3         | 19.1         | 21.8         | 21.5         | 20.8         | 19.7         | 20.1         | 20.5         |
| Depreciation              | 2.0          | 2.1          | 2.4          | 2.4          | 2.3          | 2.7          | 3.1          | 3.1          | 3.2          |
| Int. and Fin. Charges     | 1.3          | 1.1          | 1.8          | 3.0          | 3.5          | 3.3          | 3.4          | 3.0          | 2.5          |
| Interest Income           | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          |
| Other Income-rec.         | 0.7          | 0.9          | 1.7          | 2.7          | 3.2          | 2.7          | 2.2          | 3.3          | 3.4          |
| <b>PBT</b>                | <b>20.7</b>  | <b>22.6</b>  | <b>23.0</b>  | <b>28.0</b>  | <b>27.4</b>  | <b>28.2</b>  | <b>31.4</b>  | <b>37.6</b>  | <b>43.1</b>  |
| Change (%)                | 13.0         | 9.3          | 1.5          | 22.1         | -2.4         | 3.0          | 11.6         | 19.7         | 14.6         |
| Margin (%)                | 18.8         | 18.4         | 17.2         | 19.9         | 19.5         | 18.6         | 17.3         | 18.7         | 19.5         |
| Total tax                 | 3.6          | 3.7          | 4.3          | 7.6          | 8.2          | 7.3          | 8.0          | 9.6          | 11.0         |
| Tax Rate (%)              | 17.4         | 16.4         | 18.7         | 27.1         | 30.0         | 25.9         | 25.3         | 25.5         | 25.5         |
| <b>PAT</b>                | <b>17.1</b>  | <b>18.9</b>  | <b>18.7</b>  | <b>20.4</b>  | <b>19.2</b>  | <b>20.9</b>  | <b>23.5</b>  | <b>28.0</b>  | <b>32.1</b>  |
| Change (%)                | 9.1          | 10.5         | -1.3         | 9.5          | -6.3         | 9.0          | 12.5         | 19.4         | 14.6         |
| Margin (%)                | 15.5         | 15.4         | 14.0         | 14.5         | 13.7         | 13.8         | 12.9         | 14.0         | 14.5         |
| Minority interest         | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          |
| <b>Group Adjusted PAT</b> | <b>17.2</b>  | <b>17.9</b>  | <b>17.4</b>  | <b>19.8</b>  | <b>18.9</b>  | <b>20.3</b>  | <b>23.4</b>  | <b>28.0</b>  | <b>32.1</b>  |
| Non-rec. (Exp.)/Income    | -0.4         | -0.1         | -0.5         | -24.8        | -0.6         | -1.7         | -0.2         | 0.0          | 0.0          |
| <b>Reported PAT</b>       | <b>16.1</b>  | <b>17.8</b>  | <b>17.0</b>  | <b>-5.6</b>  | <b>18.5</b>  | <b>18.6</b>  | <b>23.2</b>  | <b>28.0</b>  | <b>32.1</b>  |

| Balance Sheet                  |              |              |              |              |              |              | (INR b)      |              |              |
|--------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| Y/E March                      | 2021         | 2022         | 2023         | 2024         | 2025         | 2026         | 2027E        | 2028E        | 2029E        |
| Share Capital                  | 1.0          | 1.0          | 1.0          | 1.0          | 1.0          | 1.0          | 1.0          | 1.0          | 1.0          |
| Reserves                       | 93.4         | 111.3        | 136.9        | 125.1        | 119.0        | 125.5        | 126.4        | 129.9        | 135.5        |
| Minority Int                   | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          |
| <b>Networth</b>                | <b>94.4</b>  | <b>112.3</b> | <b>137.9</b> | <b>126.1</b> | <b>120.0</b> | <b>126.5</b> | <b>127.4</b> | <b>130.9</b> | <b>136.5</b> |
| Loans                          | 17.7         | 16.1         | 10.3         | 31.5         | 38.8         | 41.4         | 33.4         | 25.4         | 19.4         |
| Deferred Liability             | -6.4         | -6.8         | -6.4         | -2.8         | 0.9          | 1.9          | 1.9          | 1.9          | 1.9          |
| <b>Capital Employed</b>        | <b>105.7</b> | <b>121.6</b> | <b>141.9</b> | <b>154.9</b> | <b>159.8</b> | <b>169.8</b> | <b>162.7</b> | <b>158.2</b> | <b>157.8</b> |
| Gross Block                    | 46.3         | 45.9         | 49.9         | 62.8         | 63.7         | 79.5         | 81.0         | 82.5         | 84.0         |
| Less: Accum. Depn.             | 8.6          | 7.5          | 8.8          | 8.8          | 9.3          | 11.9         | 15.0         | 18.2         | 21.4         |
| <b>Net Fixed Assets</b>        | <b>37.7</b>  | <b>38.4</b>  | <b>41.1</b>  | <b>54.0</b>  | <b>54.4</b>  | <b>67.6</b>  | <b>66.0</b>  | <b>64.3</b>  | <b>62.6</b>  |
| Capital WIP                    | 0.6          | 1.2          | 0.5          | 0.8          | 4.6          | 2.3          | 2.3          | 2.3          | 2.3          |
| Goodwill                       | 51.3         | 53.8         | 58.2         | 50.3         | 51.5         | 57.2         | 57.2         | 57.2         | 57.2         |
| Non Curr Investments           | 0.2          | 1.7          | 8.4          | 17.9         | 6.3          | 10.0         | 10.5         | 11.0         | 11.5         |
| Current Investments            | 6.6          | 8.4          | 21.9         | 17.2         | 31.0         | 18.5         | 18.5         | 18.5         | 18.5         |
| <b>Currents Assets</b>         | <b>39.7</b>  | <b>47.3</b>  | <b>37.9</b>  | <b>40.8</b>  | <b>45.1</b>  | <b>53.9</b>  | <b>54.7</b>  | <b>55.9</b>  | <b>61.5</b>  |
| Inventory                      | 17.2         | 21.3         | 15.4         | 12.7         | 14.2         | 16.6         | 17.4         | 17.6         | 19.4         |
| Account Receivables            | 10.0         | 11.2         | 12.5         | 15.4         | 18.2         | 18.4         | 21.9         | 24.2         | 26.7         |
| Cash and Bank Balance          | 6.7          | 7.8          | 3.9          | 5.5          | 4.8          | 10.1         | 5.3          | 3.0          | 3.4          |
| Loans and Advances             | 0.3          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          |
| Other Current Assets           | 5.5          | 7.0          | 6.1          | 7.2          | 7.9          | 8.9          | 10.2         | 11.0         | 11.9         |
| <b>Curr. Liab. &amp; Prov.</b> | <b>30.4</b>  | <b>29.2</b>  | <b>26.1</b>  | <b>26.1</b>  | <b>33.2</b>  | <b>39.6</b>  | <b>46.4</b>  | <b>51.0</b>  | <b>55.8</b>  |
| Account Payables               | 20.1         | 21.6         | 18.2         | 16.8         | 21.4         | 23.0         | 27.3         | 30.3         | 33.4         |
| Other Liabilities              | 8.4          | 5.7          | 6.1          | 6.7          | 9.2          | 13.7         | 16.0         | 17.4         | 19.0         |
| <b>Net Current Assets</b>      | <b>9.3</b>   | <b>18.1</b>  | <b>11.8</b>  | <b>14.7</b>  | <b>12.0</b>  | <b>14.3</b>  | <b>8.3</b>   | <b>4.9</b>   | <b>5.7</b>   |
| <b>Net Assets</b>              | <b>105.7</b> | <b>121.6</b> | <b>141.9</b> | <b>154.9</b> | <b>159.8</b> | <b>169.8</b> | <b>162.7</b> | <b>158.2</b> | <b>157.8</b> |

E: MOSL Estimates

## Financials and valuations

### Ratios

| Y/E March                     | 2021        | 2022        | 2023        | 2024        | 2025        | 2026        | 2027E       | 2028E       | 2029E       |
|-------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| <b>Basic (INR)</b>            |             |             |             |             |             |             |             |             |             |
| <b>EPS</b>                    | <b>16.8</b> | <b>17.5</b> | <b>17.1</b> | <b>19.3</b> | <b>18.5</b> | <b>19.8</b> | <b>22.9</b> | <b>27.4</b> | <b>31.4</b> |
| Cash EPS                      | 18.8        | 19.6        | 19.4        | 21.7        | 20.8        | 22.5        | 25.9        | 30.5        | 34.6        |
| BV/Share                      | 92.3        | 109.8       | 134.9       | 123.3       | 117.3       | 123.7       | 124.6       | 128.0       | 133.4       |
| DPS                           | 0.0         | 0.0         | 0.0         | 15.0        | 20.0        | 20.0        | 22.0        | 24.0        | 26.0        |
| Payout (%)                    | 0.0         | 0.0         | 0.0         | 77.5        | 108.0       | 100.8       | 96.1        | 87.6        | 82.8        |
| <b>Valuation (x)</b>          |             |             |             |             |             |             |             |             |             |
| P/E                           | 49.7        | 47.6        | 48.9        | 43.1        | 45.0        | 42.0        | 36.4        | 30.4        | 26.5        |
| Cash P/E                      | 44.4        | 42.6        | 43.1        | 38.4        | 40.1        | 37.1        | 32.2        | 27.4        | 24.1        |
| EV/Sales                      | 7.8         | 7.0         | 6.4         | 6.1         | 6.3         | 5.8         | 4.8         | 4.3         | 3.9         |
| EV/EBITDA                     | 37.0        | 34.5        | 33.5        | 28.0        | 29.3        | 27.8        | 24.4        | 21.4        | 18.9        |
| P/BV                          | 9.0         | 7.6         | 6.2         | 6.8         | 7.1         | 6.7         | 6.7         | 6.5         | 6.3         |
| Dividend Yield                | 0.0         | 0.0         | 0.0         | 1.8         | 2.4         | 2.4         | 2.6         | 2.9         | 3.1         |
| <b>Return Ratios (%)</b>      |             |             |             |             |             |             |             |             |             |
| RoE                           | 19.8        | 17.4        | 13.9        | 15.0        | 15.4        | 16.5        | 18.4        | 21.7        | 24.0        |
| RoCE (Post-tax)               | 17.7        | 17.4        | 15.2        | 15.2        | 13.7        | 14.2        | 15.6        | 18.9        | 21.5        |
| RoIC                          | 19.9        | 19.6        | 17.8        | 18.7        | 17.1        | 17.7        | 19.1        | 22.3        | 25.6        |
| <b>Working Capital Ratios</b> |             |             |             |             |             |             |             |             |             |
| Debtor (Days)                 | 33          | 33          | 34          | 40          | 47          | 44          | 44          | 44          | 44          |
| Asset Turnover (x)            | 2.9         | 3.1         | 3.2         | 2.6         | 2.4         | 2.2         | 2.7         | 3.0         | 3.4         |
| <b>Leverage Ratio</b>         |             |             |             |             |             |             |             |             |             |
| Debt/Equity (x)               | 0.2         | 0.1         | 0.1         | 0.3         | 0.3         | 0.3         | 0.3         | 0.2         | 0.1         |

### Cash Flow Statement

| Y/E March                    | 2021         | 2022        | 2023         | 2024         | 2025         | 2026         | 2027E        | 2028E        | 2029E        |
|------------------------------|--------------|-------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| <b>(INR b)</b>               |              |             |              |              |              |              |              |              |              |
| OP/(Loss) before Tax         | 20.8         | 21.6        | 21.3         | 2.0          | 26.7         | 25.9         | 31.4         | 37.6         | 43.1         |
| Net interest                 | 0.9          | 0.5         | 0.8          | 1.1          | 1.2          | 1.6          | 2.2          | 1.4          | 0.8          |
| Direct Taxes Paid            | -4.0         | -4.5        | -4.2         | -3.7         | -4.7         | -5.3         | -8.0         | -9.6         | -11.0        |
| (Inc)/Dec in WC              | -0.5         | -5.4        | 0.9          | -4.6         | 0.4          | 0.6          | 1.2          | 1.1          | -0.4         |
| <b>CF from Operations</b>    | <b>17.3</b>  | <b>12.2</b> | <b>18.9</b>  | <b>-5.2</b>  | <b>23.5</b>  | <b>22.8</b>  | <b>26.9</b>  | <b>30.6</b>  | <b>32.6</b>  |
| Inc in FA                    | -1.6         | -2.8        | -2.2         | -2.8         | -5.6         | -5.4         | -1.5         | -1.5         | -1.5         |
| <b>Free Cash Flow</b>        | <b>18.7</b>  | <b>11.7</b> | <b>19.3</b>  | <b>17.9</b>  | <b>20.2</b>  | <b>19.5</b>  | <b>28.7</b>  | <b>32.2</b>  | <b>34.3</b>  |
| Pur of Investments           | -0.3         | -4.7        | -16.4        | -6.1         | 0.5          | 10.4         | -0.5         | -0.5         | -0.5         |
| Others                       | -1.2         | -2.1        | 1.1          | -24.3        | 0.5          | -0.8         | 0.9          | 1.7          | 1.7          |
| <b>CF from Investments</b>   | <b>-3.1</b>  | <b>-9.6</b> | <b>-17.5</b> | <b>-33.2</b> | <b>-4.6</b>  | <b>4.2</b>   | <b>-1.1</b>  | <b>-0.3</b>  | <b>-0.3</b>  |
| Inc in Debt                  | -16.2        | -2.2        | -6.3         | 22.7         | 7.3          | 0.3          | -8.0         | -8.0         | -6.0         |
| Dividend Paid                | 0.0          | 0.0         | 0.0          | -5.1         | -25.6        | -20.5        | -22.5        | -24.6        | -26.6        |
| Interest Paid                | -1.6         | -1.1        | -1.1         | -2.6         | -3.1         | -2.8         | -3.4         | -3.0         | -2.5         |
| Other Item                   | -0.4         | -0.5        | -0.5         | -0.9         | -0.5         | -0.8         | 0.0          | 0.0          | 0.0          |
| <b>CF from Fin. Activity</b> | <b>-18.2</b> | <b>-3.8</b> | <b>-7.9</b>  | <b>14.1</b>  | <b>-21.8</b> | <b>-23.9</b> | <b>-33.9</b> | <b>-35.6</b> | <b>-35.1</b> |
| <b>Inc/Dec of Cash</b>       | <b>-1.0</b>  | <b>1.1</b>  | <b>-3.9</b>  | <b>1.6</b>   | <b>-0.6</b>  | <b>5.2</b>   | <b>-4.8</b>  | <b>-2.2</b>  | <b>0.4</b>   |
| Add: Beginning Balance       | 7.7          | 6.7         | 7.8          | 3.9          | 5.5          | 4.8          | 10.1         | 5.3          | 3.0          |
| <b>Closing Balance</b>       | <b>6.7</b>   | <b>7.8</b>  | <b>3.9</b>   | <b>5.5</b>   | <b>4.8</b>   | <b>10.1</b>  | <b>5.3</b>   | <b>3.0</b>   | <b>3.4</b>   |

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

| Explanation of Investment Rating |                                                                                              |
|----------------------------------|----------------------------------------------------------------------------------------------|
| Investment Rating                | Expected return (over 12-month)                                                              |
| BUY                              | >=15%                                                                                        |
| SELL                             | < - 10%                                                                                      |
| NEUTRAL                          | < - 10 % to 15%                                                                              |
| UNDER REVIEW                     | Rating may undergo a change                                                                  |
| NOT RATED                        | We have forward looking estimates for the stock but we refrain from assigning recommendation |

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on [www.motilaloswal.com](http://www.motilaloswal.com) > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act") and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).  
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).

6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj

Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

| Contact Person        | Contact No.                 | Email ID                     |
|-----------------------|-----------------------------|------------------------------|
| Ms. Hemangi Date      | 022 40548000 / 022 67490600 | query@motilaloswal.com       |
| Ms. Kumud Upadhyay    | 022 40548082                | servicehead@motilaloswal.com |
| Mr. Ajay Menon        | 022 40548083                | am@motilaloswal.com          |
| Mr. Neeraj Agarwal    | 022 40548085                | na@motilaloswal.com          |
| Mr. Siddhartha Khemka | 022 50362452                | po.research@motilaloswal.com |

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.